Literature DB >> 17875852

Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given.

Pia Z Pace-Asciak1, Richard J Payne, Spiro J Eski, Paul Walfish, Manzur Damani, Jeremy L Freeman.   

Abstract

OBJECTIVE: To assess the cost savings if the current policy of treating patients with a MACIS (metastases, age, completeness of resection, invasion, and size) score lower than 6 using radioactive iodine (RAI) was changed to reflect the findings of recent studies.
DESIGN: Retrospective medical record review.
SETTING: Mount Sinai Hospital, Toronto, Ontario. PATIENTS: Between January 1, 2002, and July 1, 2005, 199 consecutive patients with a MACIS score lower than 6 who received RAI treatment after total thyroidectomy. MAIN OUTCOME MEASURES: Patient demographics were analyzed. Costs for the dose of RAI, hospital stay, and health insurance claims were included in the calculations.
RESULTS: For 199 consecutive patients, the cost for sodium iodide 131 treatment totaled Can$161 588, and the required 2-day stay in isolation totaled Can$764 558. The overall cost to the health care system was Can$934 106, which translates into approximately Can$4694 per patient.
CONCLUSIONS: By following the recommendations of recent evidence-based studies and by ceasing to treat patients with a MACIS score lower than 6 after total thyroidectomy using RAI, cost savings can be accrued for health care systems involved in the treatment of thyroid cancer. Alternate strategies, such as treating patients who need RAI therapy on an outpatient basis and reducing the dose of RAI, can lower costs as well.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875852     DOI: 10.1001/archotol.133.9.870

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  4 in total

1.  Radioactive iodine in differentiated thyroid cancer: a national database perspective.

Authors:  Ryan K Orosco; Timon Hussain; Julia E Noel; David C Chang; Chrysoula Dosiou; Erik Mittra; Vasu Divi; Lisa A Orloff
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

2.  The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Ronald J Koenig; Jennifer J Griggs
Journal:  Cancer       Date:  2012-06-28       Impact factor: 6.860

3.  Use of radioactive iodine for thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

4.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.